Hepatic Fat Content and Liver Stiffness in Overweight and Obese Subjects with Non-Alcoholic Fatty Liver Disease in severe steatosis grading (grade 3) Liver Stiffness, Hepatic Fat Content, Non-Alcoholic Fatty Liver Disease, High Intensity Interval Training, Home-Based Exercise
Conditions
Interventions
High intensity interval training consisted of a 5 minutes warm up on unloaded cycling. Following the warm up, participants perform 3 loops of 3 minutes cycling at 80-85% of VO2max combined with 2 minu
Experimental Other,No Intervention No treatment
high intensity interval training,diet control
Sponsors
Research affairs, Faculty of Medicine, Chulalongkorn University
Eligibility
Sex/Gender
All
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: 1. Male and female in reproductive age 2. Age 18-50 years old 3. Severe steatosis : Controlled Attenuation Parameter (CAP) score more than or equal 310 dB/m 4. Body Mass Index : BMI = 25-34.9 kg/m2 5. Sedentary lifestyle
Exclusion criteria
Exclusion criteria: 1. Pregnancy or prepared to pregnancy in 6 months 2. CAP score equal or more than 400 dB/m 3. Alcoholic fatty liver disease (20 g. in female and 30 g. in male) 4. Fibrosis-4 (FIB-4) index equal more than 3.25, NAFLD fibrosis score (NFS) equal or more than 0.67 or liver stiffness measurement (LSM) equal or more than 10 kPa 5. Other liver deseases included hepatitis B virus (HBV), hepatitis C virus (HCV), autoimmune liver disease, celiac disease, genetic disorders such as Wilson's disease, and alpha-1-antitrypsin deficiency, hepatic malignancies, hepatobiliary infections, and biliary tract disease 6. Cardiac abnormalities detected by resting EKG and during exercise stress test with 12-lead EKG such as ischemic heart disease or other abnormalities that may be affected to exercise or did not pass the exercise stress test 7. High blood pressure during exercise stress test (more than 250/115 mmHg) 8. Injury or pain affected to exercise training 9. There are risks/contraindications for testing such as myocardial ischemia of at least 6 weeks, uncontrolled arrhythmia, etc. 10. Use drugs or supplements such as vitamin E, pioglitazone and liraglutide (if used, stop more than 3 months) 11. Diabetes mellitus with insulin injection
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Controlled attenuation parameter (CAP) score before and at 3 and 6 months after end of the intervention Transient elastography/liver fat (FibroScan) | — |
Secondary
| Measure | Time frame |
|---|---|
| Liver stiffness before and at 3 and 6 months after end of the intervention Transient elastography/liver fat (FibroScan),gamma glutamyl transferase before and at 3 and 6 months after end of the intervention blood analysis,aspartate aminotransferase before and at 3 and 6 months after end of the intervention blood analysis,alanine aminotransferase before and at 3 and 6 months after end of the intervention blood analysis,lipid profile before and at 3 and 6 months after end of the intervention blood analysis,insulin before and at 3 and 6 months after end of the intervention blood analysis,glucose before and at 3 and 6 months after end of the intervention blood analysis,% body fat before and at 3 and 6 months after end of the intervention Bioelectrical impedance analysis (BIA),body mass index before and at 3 and 6 months after end of the intervention weight, height,VO2max before and at 3 and 6 months after end of the intervention Cardiopulmonary exercise test (CPET) ,Resting metabolic rate before and at 3 and 6 months after end of the intervention lying and oxycon mobile measurement data collection | — |
Countries
Thailand
Contacts
Public ContactPeeyanit Thanawanitnam
Faculty of Medicine, Chulalongkorn University
Outcome results
None listed